Sun Pharma Advanced Research Company share news, announcements and annual reports
NSE: SPARCBSE: 532872Pharmaceuticals & BiotechnologySmall Cap
Sun Pharma Advanced Research Company Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jul 2007
Last close ₹176.46down ₹6.52 (3.56%)BSE ₹176.90
Share price at the NSE close on 30 Oct 2026. Previous close ₹182.98.
30 Oct: open ₹183.90, high ₹183.90, low ₹175.25
52-week range of traded prices to 30 Oct 2026
₹108.00Low, 23 Mar 2026₹289.00High, 8 Jul 2026
- Next results date: the board meets on 2 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹5,727 Cr778th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 3.61
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 4.28
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the latest balance sheet's; the one a year before is not on record.
- 118.4%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 84.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.42
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 6,50,81840.4% delivered
Sun Pharma Advanced Research Company board meetings
123 filed, newest first. Page 2 of 3.
Jan 2020
31 Jan · Board meeting
Nov 2019
4 Nov · Board meeting
Oct 2019
Jul 2019
29 Jul · Board meeting
May 2019
7 May · Board meeting
Apr 2019
Feb 2019
4 Feb · Board meeting
Jan 2019
22 Jan · Board meeting
Oct 2018
29 Oct · Board meeting
15 Oct · Board meeting
Jul 2018
30 Jul · Board meeting
May 2018
8 May · Board meeting
Apr 2018
24 Apr · Board meeting
Jan 2018
Oct 2017
Aug 2017
5 Aug · Board meeting
Jul 2017
May 2017
5 May · Board meeting
Apr 2017
Jan 2017
Oct 2016
28 Oct · Board meeting
Jul 2016
29 Jul · Board meeting
May 2016
6 May · Board meeting
Apr 2016
Mar 2016
7 Mar · Board meeting
Jan 2016
Nov 2015
Oct 2015
Jul 2015
May 2015
Apr 2015
21 Apr · Board meeting
Interalia, to consider and take on record the Audited Financial Results of the Company for the year ended March 31, 2015.
Jan 2015
16 Jan · Board meeting
Interalia, to consider and take on record the Un-audited Financial Results of the Company for the third quarter ended December 31, 2014.
Oct 2014
17 Oct · Board meeting
Interalia to consider and take on record the Unaudited Financial Results of the Company for the second quarter / half year ended September 30, 2014.
Jul 2014
16 Jul · Board meeting
Interalia, to consider and take on record the Un-audited Financial Results of the Company for the first quarter ended June 30, 2014. Further that window closure for Trading by Designated persons as per Insider Trading Rules of the Company will be from July 22, 2014 to August 04, 2014 (both days inclusive).
Apr 2014
Jan 2014
17 Jan · Board meeting
Interalia, to consider and take on record the Un-audited Financial Results of the Company for the third quarter ended December 31, 2013.
Oct 2013
15 Oct · Board meeting
Interalia, to consider and take on record the Un-audited Financial Results of the Company for the second quarter /half year ended September 30, 2013.
Jul 2013
16 Jul · Board meeting
Interalia, to consider and take on record the Un-audited Financial Results of the Company for the first quarter ended June 30, 2013.
Apr 2013
26 Apr · Board meeting
Interalia, to consider and approve the Audited Financial Results of the Company for the year ended March 31, 2013.
Jan 2013
9 Jan · Board meeting
Interalia, to consider and take on record the Unaudited Financial Results of the Company for the third quarter ended December 31, 2012.
Oct 2012
16 Oct · Board meeting
Interalia, to consider and take on record the Unaudited Financial Results of the Company for the second quarter ended September 30, 2012.